RU2218919C2 - Гетероциклические виниловые эфиры, обладающие активностью в отношении неврологических заболеваний - Google Patents
Гетероциклические виниловые эфиры, обладающие активностью в отношении неврологических заболеваний Download PDFInfo
- Publication number
- RU2218919C2 RU2218919C2 RU2000106044/14A RU2000106044A RU2218919C2 RU 2218919 C2 RU2218919 C2 RU 2218919C2 RU 2000106044/14 A RU2000106044/14 A RU 2000106044/14A RU 2000106044 A RU2000106044 A RU 2000106044A RU 2218919 C2 RU2218919 C2 RU 2218919C2
- Authority
- RU
- Russia
- Prior art keywords
- group
- nitrogen atom
- alkyl
- ness
- compound
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Изобретение относится к области медицины, а именно к фармакологии, и может иметь отношение к лечению неврологических заболеваний. Используют соединение общей формулы (I)
в которой R обозначает галоген или (низш.)алкил, n = 0-3; R1 обозначает (низш. )алкил, циклоалкил, бензил, необязательно замещенный гидроксигруппой, галогеном, (низш.)алкоксигруппой или (низш.)алкилом, бензоил, необязательно замещенный амино-, (низш.)алкиламино- или ди(низш.)алкиламиногруппой, ацетил или циклоалкилкарбонил и
в которой R обозначает галоген или (низш.)алкил, n = 0-3; R1 обозначает (низш. )алкил, циклоалкил, бензил, необязательно замещенный гидроксигруппой, галогеном, (низш.)алкоксигруппой или (низш.)алкилом, бензоил, необязательно замещенный амино-, (низш.)алкиламино- или ди(низш.)алкиламиногруппой, ацетил или циклоалкилкарбонил и
Description
Текст описания в факсимильном виде (см. графическую часть) Т
Claims (6)
1. Лекарственное средство, обладающее антагонистической и/или агонистической активностью в отношении метаботропного глутаматного рецептора, содержащее в качестве терапевтически активного вещества соединение общей формулы
в которой R обозначает галоген или (низш.)алкил;
n=0-3;
R1 обозначает (низш.)алкил, циклоалкил, бензил, необязательно замещенный гидроксигруппой, галогеном, (низш.)алкоксигруппой или (низш.)алкилом, бензоил, необязательно замещенный амино-, (низш.)алкиламино- или ди(низш.)алкиламиногруппой, ацетил или циклоалкилкарбонил;
обозначает ароматический 5-членный фрагмент, который присоединен через атом азота и который, кроме связывающего атома азота, дополнительно содержит 1-3 атома азота,
а также его фармацевтически приемлемые соли.
2. Лекарственное средство по п.1, содержащее в качестве терапевтически активного вещества соединение общей формулы I, где R обозначает хлор, n=1 или 2,
3. Лекарственное средство по п.2, содержащее в качестве терапевтически активного вещества соединение, выбранное из группы, включающей
1-[2-(2,4-дихлорфенил)-2-циклогексилоксивинил]-1Н-[1,2,4]триазол,
1-[2-(2,4-дихлорфенил)-2-бензилоксивинил]-1Н-тетразол,
1-[2-(4-хлорфенил)-2-бутоксивинил]-1Н-тетразол,
1-[2-(4-хлорфенил)-2-бутоксивинил]-1Н-[1,2,4]триазол и
1-[2-(2,6-дихлорфенил)-2-бутоксивинил]-1Н-[1,2,4]триазол.
6. Соединение по п.5, представляющее собой 1-[2-(2,4-дихлорфенил)-2-циклогексилоксивинил]-1Н-[1,2,4]триазол.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97114065.2 | 1997-08-14 | ||
EP97114065 | 1997-08-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000106044A RU2000106044A (ru) | 2002-05-10 |
RU2218919C2 true RU2218919C2 (ru) | 2003-12-20 |
Family
ID=8227219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000106044/14A RU2218919C2 (ru) | 1997-08-14 | 1998-08-06 | Гетероциклические виниловые эфиры, обладающие активностью в отношении неврологических заболеваний |
Country Status (24)
Country | Link |
---|---|
US (2) | US6054588A (ru) |
EP (1) | EP1003505B1 (ru) |
JP (1) | JP3593031B2 (ru) |
KR (1) | KR100357650B1 (ru) |
CN (1) | CN1154489C (ru) |
AR (1) | AR016604A1 (ru) |
AT (1) | ATE262331T1 (ru) |
AU (1) | AU741532B2 (ru) |
BR (1) | BR9811933A (ru) |
CA (1) | CA2297732C (ru) |
DE (1) | DE69822638T2 (ru) |
ES (1) | ES2216305T3 (ru) |
HR (1) | HRP20000079A2 (ru) |
HU (1) | HUP0004412A3 (ru) |
ID (1) | ID28529A (ru) |
IL (1) | IL134168A0 (ru) |
NO (1) | NO20000738L (ru) |
NZ (1) | NZ502463A (ru) |
PL (1) | PL192029B1 (ru) |
RU (1) | RU2218919C2 (ru) |
TR (1) | TR200000405T2 (ru) |
WO (1) | WO1999008678A1 (ru) |
YU (1) | YU6100A (ru) |
ZA (1) | ZA987145B (ru) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0115871A (pt) | 2000-12-04 | 2003-10-28 | Hoffmann La Roche | Derivados de feniletenila ou feniletinila como antagonistas de receptores de glutamato |
JP2005502618A (ja) * | 2001-06-04 | 2005-01-27 | ザ・ジェネラル・ホスピタル・コーポレイション | 光力学的化合物を用いて脆弱なプラークを検出および治療する方法 |
DE10205057A1 (de) * | 2002-02-07 | 2003-08-14 | Bayer Cropscience Ag | Substituierte 4-Hetaryl-pyrazoline |
WO2004078715A1 (ja) | 2003-03-07 | 2004-09-16 | Astellas Pharma Inc. | 2,6-ジ置換スチリルを有する含窒素へテロ環誘導体 |
TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
KR100907108B1 (ko) | 2004-06-01 | 2009-07-09 | 에프. 호프만-라 로슈 아게 | Mglu5 수용체 길항제로서 피리딘-4-일-에틴일-이미다졸및 피라졸 |
ITVA20050050A1 (it) * | 2005-08-05 | 2007-02-06 | Lamberti Spa | Sistemi fotopolimerizzabili contenenti coiniziatori fotoreticolabili a bassa estraibilita' e volatilita' |
TWI417095B (zh) * | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
LT2083811T (lt) | 2006-11-22 | 2017-01-25 | Clinical Research Associates, Llc | Dauno sindromo, trapiosios x chromosomos sindromo ir autizmo gydymo būdai |
CN101568531B (zh) | 2006-12-21 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | Mglur5受体拮抗剂的多晶型物 |
TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
PT2200985E (pt) | 2007-09-14 | 2011-07-21 | Ortho Mcneil Janssen Pharm | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas |
JP5433579B2 (ja) * | 2007-09-14 | 2014-03-05 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 1,3−二置換−4−フェニル−1h−ピリジン−2−オン |
UA100126C2 (en) | 2007-09-14 | 2012-11-26 | Аддекс Фарма С.А. | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones |
CN101861316B (zh) * | 2007-11-14 | 2013-08-21 | 奥梅-杨森制药有限公司 | 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
AU2009289784B2 (en) | 2008-09-02 | 2012-03-22 | Addex Pharma S.A. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
RU2517181C2 (ru) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов |
BRPI0921333A2 (pt) | 2008-11-28 | 2015-12-29 | Addex Pharmaceuticals Sa | derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos |
KR101753826B1 (ko) | 2009-05-12 | 2017-07-04 | 얀센 파마슈티칼즈, 인코포레이티드 | 1,2,4―트리아졸로[4,3―a]피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도 |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
BRPI1010831A2 (pt) | 2009-05-12 | 2016-04-05 | Addex Pharmaceuticals Sa | derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2 |
EP2544688B1 (en) | 2010-03-02 | 2016-09-07 | President and Fellows of Harvard College | Methods and compositions for treatment of angelman syndrome |
WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
US20120016021A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
EP2649069B1 (en) | 2010-11-08 | 2015-08-26 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
AU2011328203B2 (en) | 2010-11-08 | 2015-03-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
CN102506473B (zh) * | 2011-10-18 | 2014-06-11 | 江苏七彩科技有限公司 | 直接蒸发式冰蓄冷制冷系统及其制冷方法 |
CN102690240B (zh) * | 2012-06-07 | 2014-09-10 | 郑州大学 | 三氮唑烯醚类、肟醚类化合物及其制备方法与应用 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
MX2016009471A (es) | 2014-01-21 | 2016-10-13 | Janssen Pharmaceutica Nv | Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso. |
HUE045610T2 (hu) | 2014-01-21 | 2020-01-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk |
CN106279038A (zh) * | 2016-08-16 | 2017-01-04 | 湖南中威制药有限公司 | 一种硝酸奥昔康唑原料药的合成方法 |
KR102635936B1 (ko) | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
AU2017374458B2 (en) * | 2016-12-14 | 2023-03-02 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
KR20230066244A (ko) | 2021-11-06 | 2023-05-15 | 김경민 | 점선식 포장지 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4330545A (en) | 1977-02-21 | 1982-05-18 | Siegfried Aktiengesellschaft | Heterocyclic imidazolyl vinyl ethers and use of same as fungicides or bactericides |
DE2839388A1 (de) | 1978-09-11 | 1980-03-27 | Siegfried Ag | Imidazolylvinylaether und deren verwendung |
CH648552A5 (de) * | 1981-01-23 | 1985-03-29 | Siegfried Ag | Verfahren zur herstellung von imidazolylvinylethern. |
EP0079856A1 (de) * | 1981-11-12 | 1983-05-25 | Ciba-Geigy Ag | Mikrobizide Triazolyl-vinyläther |
DE3417468A1 (de) * | 1984-05-11 | 1985-11-14 | Bayer Ag, 5090 Leverkusen | Azolylvinylether |
US5658943A (en) * | 1995-01-05 | 1997-08-19 | Warner-Lambert Company | Phenylalanine derivatives as endothelin antagonists |
-
1998
- 1998-08-06 YU YU6100A patent/YU6100A/sh unknown
- 1998-08-06 RU RU2000106044/14A patent/RU2218919C2/ru not_active IP Right Cessation
- 1998-08-06 AU AU91593/98A patent/AU741532B2/en not_active Ceased
- 1998-08-06 ES ES98943851T patent/ES2216305T3/es not_active Expired - Lifetime
- 1998-08-06 KR KR1020007001480A patent/KR100357650B1/ko not_active IP Right Cessation
- 1998-08-06 CN CNB988079917A patent/CN1154489C/zh not_active Expired - Fee Related
- 1998-08-06 NZ NZ502463A patent/NZ502463A/en unknown
- 1998-08-06 HU HU0004412A patent/HUP0004412A3/hu unknown
- 1998-08-06 EP EP98943851A patent/EP1003505B1/en not_active Expired - Lifetime
- 1998-08-06 AT AT98943851T patent/ATE262331T1/de not_active IP Right Cessation
- 1998-08-06 CA CA002297732A patent/CA2297732C/en not_active Expired - Fee Related
- 1998-08-06 BR BR9811933-8A patent/BR9811933A/pt not_active Application Discontinuation
- 1998-08-06 PL PL338637A patent/PL192029B1/pl unknown
- 1998-08-06 WO PCT/EP1998/004890 patent/WO1999008678A1/en not_active Application Discontinuation
- 1998-08-06 JP JP2000509418A patent/JP3593031B2/ja not_active Expired - Fee Related
- 1998-08-06 IL IL13416898A patent/IL134168A0/xx unknown
- 1998-08-06 ID IDW20000212A patent/ID28529A/id unknown
- 1998-08-06 TR TR2000/00405T patent/TR200000405T2/xx unknown
- 1998-08-06 DE DE69822638T patent/DE69822638T2/de not_active Expired - Fee Related
- 1998-08-07 ZA ZA987145A patent/ZA987145B/xx unknown
- 1998-08-12 AR ARP980103977A patent/AR016604A1/es not_active Application Discontinuation
-
1999
- 1999-05-04 US US09/304,624 patent/US6054588A/en not_active Expired - Fee Related
- 1999-05-04 US US09/304,909 patent/US6248901B1/en not_active Expired - Fee Related
-
2000
- 2000-02-11 HR HR20000079A patent/HRP20000079A2/hr not_active Application Discontinuation
- 2000-02-14 NO NO20000738A patent/NO20000738L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU741532B2 (en) | 2001-12-06 |
IL134168A0 (en) | 2001-04-30 |
HUP0004412A2 (hu) | 2001-07-30 |
ATE262331T1 (de) | 2004-04-15 |
KR100357650B1 (ko) | 2002-10-25 |
NO20000738D0 (no) | 2000-02-14 |
PL338637A1 (en) | 2000-11-06 |
PL192029B1 (pl) | 2006-08-31 |
HRP20000079A2 (en) | 2000-12-31 |
US6248901B1 (en) | 2001-06-19 |
ZA987145B (en) | 1999-02-15 |
EP1003505B1 (en) | 2004-03-24 |
ES2216305T3 (es) | 2004-10-16 |
NO20000738L (no) | 2000-04-11 |
DE69822638D1 (de) | 2004-04-29 |
NZ502463A (en) | 2002-05-31 |
YU6100A (sh) | 2002-10-18 |
CA2297732C (en) | 2008-04-29 |
CN1266368A (zh) | 2000-09-13 |
AU9159398A (en) | 1999-03-08 |
TR200000405T2 (tr) | 2000-08-21 |
WO1999008678A1 (en) | 1999-02-25 |
JP2001515037A (ja) | 2001-09-18 |
KR20010022877A (ko) | 2001-03-26 |
AR016604A1 (es) | 2001-07-25 |
ID28529A (id) | 2001-05-31 |
CN1154489C (zh) | 2004-06-23 |
DE69822638T2 (de) | 2005-02-24 |
BR9811933A (pt) | 2000-09-05 |
US6054588A (en) | 2000-04-25 |
HUP0004412A3 (en) | 2003-06-30 |
EP1003505A1 (en) | 2000-05-31 |
CA2297732A1 (en) | 1999-02-25 |
JP3593031B2 (ja) | 2004-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2218919C2 (ru) | Гетероциклические виниловые эфиры, обладающие активностью в отношении неврологических заболеваний | |
RU2000106044A (ru) | Гетероциклические виниловые эфиры, обладающие активностью в отношении неврологических заболеваний | |
RU2317294C2 (ru) | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора | |
US11957657B2 (en) | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | |
RU2325382C2 (ru) | Производные 1h-1,2,4-триазол-3-карбоксамида в качестве лигандов рецептора каннабиноидов | |
ES2285522T3 (es) | 1-(2,3-dimetil,fenil)-etil-1,3-dihidro-imidazol-2-tiona como agonista alfa 2a no sedante. | |
DE60012751T2 (de) | Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz | |
JPH06293740A (ja) | アゾール化合物、その製造方法及びその用途 | |
EP2298757A3 (en) | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | |
BR9408343A (pt) | Derivados 5-(2-imidazolinil amino) benzimidazol sua preparação e seu uso como agonistas alfa-2 adrenoceptor | |
RU2002110107A (ru) | Производные бензодиазепина | |
JP2005536475A5 (ru) | ||
JP2005518337A5 (ru) | ||
JP2005524628A5 (ru) | ||
RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
RU2005102110A (ru) | Способ и лекарственное средство для лечения тяжелой сердечной недостаточности | |
WO2003084527A1 (fr) | Agent therapeutique pour la prevention d'etat septique grave | |
US4208417A (en) | Indole derivatives and their use as anxiolytics | |
Hanna et al. | Synthesis and pharmacological evaluation of some novel 5-(pyrazol-3-yl) thiadiazole and oxadiazole derivatives as potential hypoglycemic agents | |
AU1922888A (en) | Dioxolanylmethyl -1H- 1,2,4-triazole derivatives | |
RU2224765C1 (ru) | Полипептидное соединение, способы его получения, фармацевтическая композиция и способ профилактики или лечения грибковых заболеваний | |
KR950702544A (ko) | 비페닐메탄 유도체 및 이를 함유하는 약제 | |
CA2005976A1 (en) | Agents containing imidazoline derivatives for systemic combating of ecto-parasites in host animals and novel imidazoline derivatives | |
KR870011105A (ko) | 1,3-치환된 이미다졸륨 염 | |
KR20200033224A (ko) | 원형 탈모증의 치료제 또는 예방제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20080807 |